risankizumab   Click here for help

GtoPdb Ligand ID: 8922

Synonyms: ABBV-066 | BI 655066 | BI-655066 | risankizumab-rzaa | Skyrizi®
Approved drug Immunopharmacology Ligand
risankizumab is an approved drug (Japan, FDA & EMA (2019))
Compound class: Antibody
Comment: Risankizumab (research code BI 655066) is a humanised monoclonal antibody targeting interleukin 23A (IL-23A) [11]. It was developed through collaboration between Boehringer Ingelheim and AbbVie for the treatment of autoinflammatory diseases.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
1. Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN. (2019)
Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Br J Dermatol, 180 (6): 1348-1351. [PMID:30632140]
2. Baeten DL, Kuchroo VK. (2013)
How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases.
Nat Med, 19 (7): 824-5. [PMID:23836225]
3. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gutin A, Abkevic V, Burden AD et al.. (2007)
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.
Hum Genet, 122 (2): 201-6. [PMID:17587057]
4. D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A et al.. (2022)
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
The Lancet, 399 (10340): 2015-2030. DOI: 10.1016/S0140-6736(22)00467-6
5. Elmaagacli AH, Koldehoff M, Landt O, Beelen DW. (2008)
Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation.
Bone Marrow Transplant, 41 (9): 821-6. [PMID:18209723]
6. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A et al.. (2022)
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
The Lancet, 399 (10340): 2031-2046. DOI: 10.1016/S0140-6736(22)00466-4
7. Gaffen SL, Jain R, Garg AV, Cua DJ. (2014)
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.
Nat Rev Immunol, 14 (9): 585-600. [PMID:25145755]
8. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P et al.. (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet, 392 (10148): 650-661. [PMID:30097359]
9. Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, Lalovic B, Aslanyan S, Wang EE, Hall D et al.. (2015)
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
J Allergy Clin Immunol, 136 (1): 116-124.e7. [PMID:25769911]
10. McGovern D, Powrie F. (2007)
The IL23 axis plays a key role in the pathogenesis of IBD.
Gut, 56 (10): 1333-6. [PMID:17872562]
11. Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, He Y, Raymond EL, Ahlberg J, Frego LE et al.. (2015)
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody.
MAbs, 7 (4): 778-91. [PMID:25905918]
12. Toussirot E. (2012)
The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Inflamm Allergy Drug Targets, 11 (2): 159-68. [PMID:22280236]